Xarelto Lawsuit Plaintiffs Highlight Studies Which Cause Concern Over Blood Thinner’s Side Effects

January 07, 2016 – – BloodThinnerHelp.com reports on the conclusions of two studies which have caused much concern regarding blood-thinning drug Xarelto and dangerous, uncontrollable bleeding episodes. The drug is manufactured by Bayer AG and Janssen Pharmaceuticals, (a division of parent company Johnson & Johnson). Each of the two published studies appear to link the blood thinner to dangerous and even fatal side effects for consumers using it.

In 2011, Xarelto was approved by the U.S. Food and Drug Administration, and was released to the market as a revolutionary new type of blood thinner. It was initially approved to treat patients who had recently undergone hip or knee replacement surgeries by preventing blood clots during the healing process. Xarelto’s approved use was later expanded by the FDA, who also approved the drug to treat patients with atrial fibrillation, deep vein thrombosis, or pulmonary embolism.

After its first year on the market, however, the drug quickly became considered an especially dangerous one. It was linked to hundreds of reports of adverse bleeding events, and patients across the nation claimed it had caused them blood clots, strokes, internal bleeds, and uncontrollable bleeding episodes.

One study that helped to highlight some serious issues with the blood thinner was completed by physicians Judy H. Hun and John C. Hwang. The doctors noted that three of their patients had developed spontaneous eye bleeding episodes while using Xarelto, and decided to collectively look into the matter. Their studies concluded that the risk of eye bleeding appeared to be increasingly elevated for those patients who had switched from using a traditional blood thinner, such as warfarin, to using Xarelto.

An additional study concerning these same issues ran from October 1st 2010 to March 31st, 2012, and evaluated many people from across the nation who were using Xarelto, Pradaxa, and warfarin as blood thinners. The final sample of patients involved included 46,000 total, 39,607 of which used warfarin, 4,907 of which used Pradaxa, and 1,649 of which used Xarelto. Research done on these individuals showed “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”

Today, lawsuits filed against Xarelto number over 2,800 cases in federal court. They have been consolidated to form multidistrict litigation number 2592, and are being overseen in the Eastern District of Louisiana by Judge Eldon Fallon. As they await trial, they are expected to increase in number. These federal court cases are also joined by over 500 others which form a mass tort group in Philadelphia, Pennsylvania.

Attorney Joseph Osborne is currently working to assist anyone who has used Xarelto and suffered from adverse health events. He believes that these patients may be entitled to significant compensation, and deserve the opportunity to fully explore their legal rights. At the time, he is offering free consultations for those who qualify.

To obtain more information regarding Xarelto bleeding lawsuits, or to ask questions, please call Attorney Osborne at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60007009